688,161 Shares in Omnicell, Inc. (NASDAQ:OMCL) Acquired by Toronto Dominion Bank

Toronto Dominion Bank purchased a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 688,161 shares of the company's stock, valued at approximately $30,637,000. Toronto Dominion Bank owned 1.49% of Omnicell as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after buying an additional 273 shares during the period. Johnson Financial Group Inc. bought a new position in Omnicell in the 4th quarter worth approximately $37,000. Van ECK Associates Corp increased its position in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after buying an additional 315 shares during the period. Headlands Technologies LLC bought a new position in Omnicell in the 4th quarter worth approximately $53,000. Finally, First Horizon Advisors Inc. increased its position in Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after buying an additional 355 shares during the period. 97.70% of the stock is owned by institutional investors.

Analysts Set New Price Targets

OMCL has been the topic of a number of research reports. Benchmark lowered their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Wells Fargo & Company boosted their price objective on Omnicell from $35.00 to $37.00 and gave the company an "overweight" rating in a research report on Friday. JPMorgan Chase & Co. lowered their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Bank of America boosted their price objective on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Friday. Finally, Wall Street Zen upgraded Omnicell from a "hold" rating to a "buy" rating in a research report on Tuesday. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Omnicell presently has an average rating of "Moderate Buy" and a consensus target price of $44.83.

Omnicell Price Performance

NASDAQ:OMCL traded down $0.61 during trading hours on Friday, reaching $28.23. The company had a trading volume of 760,523 shares, compared to its average volume of 564,978. The stock has a 50-day moving average of $30.94 and a two-hundred day moving average of $38.72. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.75. The firm has a market capitalization of $1.32 billion, a PE ratio of 104.56, a PEG ratio of 7.53 and a beta of 0.78. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.16 by $0.10. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The firm had revenue of $269.67 million for the quarter, compared to analysts' expectations of $260.18 million. During the same period in the prior year, the business posted $0.03 earnings per share. The business's revenue was up 9.5% compared to the same quarter last year. Analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.